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Deferent to the indication for surgical resection of liver
metastases in previous years number, location and size
are not the main targets to define resectability any more
but the volume of the so called liver remnant, which has
to have adequate inflow, outflow and biliary drainage.
The magnitude of the remnant is dependent upon the
function of the liver which nowadays is not only ham-
pered by a potential underlying liver disease but very
often damaged by previous extensive chemotherapy [1].
Liver surgery has become a safe procedure as a result
of improved techniques, interdisciplinary management
in radiologic assessment, oncological understanding,
perioperative care and surgical specialisation.
When a patient is newly diagnosed with metastatic col-
orectal cancer (mCRC) the following issues should be dis-
cussed primarily in a multidisciplinary meeting: timing of
metastatic diagnosis (metachronous/synchronous), pri-
mary insitu (yes/no; clinically symptomatic: y/n), affected
organs, comorbidities, resectability status. Especially the
last point has no general rules and is dependent upon the
experience of the team and the specialised surgeon.
Initial resectability is categorized into three groups:
resectable, potentially resectable (after downsizing
through chemotherapy), unresectable [2]; the belonging
of each patient to one of these groups can change within
its course of disease and should therefore be rediscussed
routinely every two months.
Every newly diagnosed mCRC patient should receive at
least a short course of systemic chemotherapy (e.g. two
months) to estimate his/her aggressiveness of disease and
thereby define the right surgical candidate (the responding
patient). Chemotherapy has become very effective with
response rates (defined as complete or partial radiological
response) in liver limited disease approaching 80% with
very small percentage numbers of progressive disease
(<5%) [3].
If a patient’s disease has demonstrated to respond to
chemotherapy every attempt should be made to perform
resection with potential curative request in a fit patient
who can tolerate major surgery. The technical options
are various and range from a simple removal of half of
the liver to the addition of resection of lesions in the
remaining lobe or their destruction by thermal energy.
This can be done after an increase of the initially too
small remnant by using portal vein embolization (PVE)
or by the use of a so called two stage procedure where
one lobe is cleared of metastases at the first operation
and the other lobe is resected secondarily after hypertro-
phy of the initially treated lobe (mostly with the addition
of PVE). The resection itself is nowadays a bloodless pro-
cedure especially if sophisticated methods are used (e.g.
CUSA technique) with the requirement of transfusions in
less than 10% of patients in experienced centres [4].
Postoperative care is essential for the outcome of the
patients and should include specialised anesthesiological
surveillance and medical oncology advice after patholo-
gical work up of the resected metastases.
With this multidisciplinary approach to mCRC
patients overall outcome has improved and reached
median survival figures of 5 years [5].
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